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Introduction
 Molecular chaperones form complexes with client proteins to 
assure proper folding and trafficking [1]. Heat-shock protein 90 
(Hsp90) is a conserved chaperone that interacts with hundreds of 
clients. Cancer cells require Hsp90 to protect and keep oncoproteins 
in appropriate forms necessary for their activity and survival [2].
 Cancer cells are known to have an altered metabolism, with 
glycolysis becoming their predominant means of acquiring energy 
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even in the presence of oxygen [3]. This switch in energy production 
is called the “Warburg effect” [4]. In cancer cells, one of the most 
important enzymes in the process of glycolysis is Hexokinase II (HK 
II). In particular, a strong correlation between HK II expression and 
tumor size, differentiation, as well as tumor stage, has been shown in 
gastric cancer [5]. Furthermore, the malignant potential of pancreatic 
cancer has been correlated to the expression of HK II in the tumor 
tissue [6]. While HK II is responsible for metabolizing glucose 
into glucose-6-phosphate [7], the enzyme activity depends on its 
subcellular localization. HK II has greater activity when attached 
to the Outer Mitochondrial Membrane (OMM) through 
Voltage Dependent Anion Channels (VDACs); this localization 
facilitates access of the enzyme to the ATP pool [8]. Interestingly, 
facilitated detachment of HK II from VDAC in cancer cells was found 
to be necessary in increasing mitochondrial activity and therefore, 
shifting cellular metabolism towards oxidative phosphorylation [9].
 The main question of the present study was to determine the effects 
of blocking Hsp90 on cancer cell metabolism. Hsp90 is also present 
in non-transformed cells; however, its activity in non-cancerous cells 
was not the subject of the present study. Some reports have shown 
that Hsp90 does not affect glucose uptake, which would exclude a 
direct interaction of Hsp90 with plasma membrane glucose 
transporters [10]. Also, proteomic studies of the cells treated with 
Hsp90 inhibitors did not reveal any changes in HK II expression [11]. 
Hsp90 affects the assembly of elements of the mitochondrial TOM 
complex into mitochondrial membranes [12,13]. The latter underlies 
the hypothesis of the present study that disruption of the TOM 
complex by Hsp90 inhibition will result in a lower abundance 
of functional VDACs in the mitochondrial membrane and, as a 
consequence, in reduced glycolytic activity of the cells. Here we 
provide a mechanism by which blocking Hsp90 affects Tom40, VDAC 
and HK II abundance in mitochondria, as well as the influence of this 
mitochondrial imbalance on cancer cell metabolism.
Materials and Methods
Cell culture
 MiaPaCa-2 pancreatic cancer cells and TMK-1 gastric cancer 
cells were obtained from ATCC (Manassas, VA, USA). The murine 
pancreatic cancer cell line Panc02 was kindly provided by Prof. 
Volker Schmitz (University of Bonn, Bonn, Germany). Cells were 
grown in DMEM medium with 15% (MiaPaCa-2) and 10% (TMK-1 
and Panc02) fetal bovine serum supplemented with glutamine, 
pen-strep and vitamins. Cells were grown in 10 cm petri dishes 
(unless otherwise indicated in the text) and maintained in a 
humidified incubator kept at 37°C with 5% CO2. The water-soluble 
Hsp90 inhibitor 17-DMAG (17-Dimethylaminoethylamino-17deme-
thoxygeldanamycin) was obtained from Invivogen (Toulouse, France).
Transient siRNA transfection
 To inhibit Tom40 expression, transient down-regulation by 
RNAi was applied using a siRNATom40 designed by Qiagen (Hilden, 
Germany). TMK-1 and MiaPaCa-2 cancer cells were plated at about 
50% cell density and were transiently transfected with siRNATom40 
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using Lipofectamine (Qiagen), according to the manufacturer’s 
instructions. Administration of Lipofectamine (mock) or scrambled 
RNA (neg. ctrl.) served as controls. Knock-down was confirmed by 
Western blotting for Tom40. 
Extraction of mitochondrial protein and determination of 
hexokinase activity
 Mitochondria were extracted in two different ways. a) For 
protein expression studies, cells were grown in 75-cm2 flasks and 
incubated for 72 h before cell harvest in the presence or absence of 
17-DMAG (100 nM). A mitochondria isolation kit (Qiagen) was used 
to protein. b) The hexokinase-mitochondrial fraction was extracted 
as described by [14]. Enzyme activity was measured in cytosolic and 
mitochondrial fractions separately using a VarioScan 
spectrophotometer from Thermo Scientific (Waltham, MA, USA). 
The measurements were recorded at 30°C, every 10 seconds for one 
hour. Enzyme activity was assessed as described by [14].
Western blotting and co-immunoprecipitation
 Western blotting was performed from cytosolic and mitochondrial 
protein as described before [15,16]. Antibodies to HK I, HK II, HK 
III, Hsp90, Tom40, VDAC (for all 3 isoforms), PDI and β-actin were 
purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
 For co-Immunoprecipitation (co-IP) experiments, cells were left 
untreated (control) or cultured in the presence of 17-DMAG (100 
nM). Briefly, 500 μg of mitochondrial protein together with 1 μg of 
Tom40-specific antibody was mixed for 1 h at 4°C. After incubation, 
25 μL of agarose beads (Santa Cruz Biotechnology) were added 
and samples were mixed overnight at 4°C in elution buffer from 
Pierce Co-Immunoprecipitation Kit (Thermo Scientific, Waltham, 
MA, USA). Samples were then washed 5 times with 500 μL elution 
buffer and protein was collected; Western blotting was performed as 
described previously [15,16]. 
Immunocytochemistry
 Cell staining was performed as described before [17]. Briefly, cells 
were grown in 24-well plates on glass inserts. For all types of staining, 
cells were fixed in 5% paraformaldehyde, permeabilised with 0.1% 
saponin, blocked with antibody dilution buffer (DCS Innovative 
Diagnostik-Systeme, Hamburg, Germany) and incubated with 
Mitotracker (Invitrogen, Carlsbad, CA, USA) for 30 minutes followed 
by application of the appropriate antibody specific for VDAC, HK II 
or Tom40 (Santa Cruz Biotechnologies) for 1 hour. Coverslips were 
then mounted in DAKO (Glostrup, Denmark) 
fluorescent-mounting media. Photos were taken using a Zeiss Axio 
Vision microscope (Oberkochen, Germany) and the analysis 
performed using ImageJ software. For each condition at least 150 cells 
were observed from 3 independent experiments.
Metabolomics
 For metabolic analysis, 500,000 cells were plated into 10 cm petri 
dishes and treated with 100nM 17-DMAG, siRNATom40, control 
siRNA (Qiagen), and control medium, respectively. After 24 h, cells 
were washed once with PBS and media containing 4 mM [U-13C] 
glucose was added. After 48h, cells were harvested and extracted 
as previously described [18] using 10 µL of 1mM [2H7] 
trans-cinnamic acid (Sigma-Aldrich/Fluka, Taufkirchen, Germany) as 
extraction standard. Samples were reconstituted in 200 µL of water 
for HPLC-MS/MS analysis, and 10 µL of this extract was injected into 
an Agilent 1200 SL HPLC system (Böblingen, Germany) coupled to 
a ABSciex API 4000 QTrap mass spectrometer (ABSciex, Darmstadt, 
Germany) equipped with a TurboV electrospray ion source operated 
in negative mode. A Phenomenex Luna NH2 (150 × 2 mm i.d., 3 µm, 
Torrence, CA, USA) column with mobile phases A [0.1% (v/v) formic 
acid (Sigma-Aldrich) in PURELAB Plus water] and B [acetonitrile 
(LC-MS grade, Sigma-Aldrich)] at 250 µL/min was used employing 
the following gradient: 100% A (8 min); 100% A to 0% A from 8-10 
min; 0% A (5 min); 0% A to 100% A from 15-16 min; 100% A (6 min). 
MS/MS analysis was performed in Multiple Reactions Monitoring 
(MRM) using one transition each for the unlabelled analyte and the 
labelled analogue(s). Ion ratios were calculated from the sum of the 
peak areas of monitored labelled substrates divided by the area of the 
unlabeled analogue. For succinate +2 and +4 isotopes were combined 
throughout all labelling experiments. For overall statistical analyses, 
two-sided t-tests were used assuming unequal variances between 
groups. 
 Labelled and unlabelled serine and glycine in 10 µL of media 
were derivatized with propyl chloroformate and analysed by 
HPLC-ESI-MS/MS as described previously [19]. The MRM 
transitions were programmed separately for unlabeled and fully 
labelled serine and glycine. To determine lactate release, 10 µL of 
medium were dried by means of a vacuum evaporator 
(CombiDancer, Hettich AG, Bäch, Switzerland), subjected to 
methoximation and silylation and analyzed by GC EI-qMS [20]. 
Lactate ion ratios were calculated from ions m/z 219 and 222 for 
unlabeled and fully labelled lactate derivative, respectively.
Animal experiments
 For in vivo experiments, 1 × 105 murine Pancreatic cancer cells 
(Panc02) were injected into the right flank of BL6 mice [15,16]. 
Treatment was initiated after 8 days when tumors had reached a size 
of 90-100 mm3. Mice received an initial loading dose of 25 mg/kg 
17-DMAG and, thereafter, a maintenance dose of 10 mg/kg 17-DMAG 
every other day via intraperitoneal injection. Mice were sacrificed 
after 17 days of treatment and tumors were excised for analysis.
Statistics
 The data are presented as the average ±SD; n≥3. To assess 
statistical significance treated samples were compared to control 
values. For the experiments in (Figures 1-3) ANOVA followed by a 
TukeyHSD test was used for multiple group comparison. For all the 
other experiments unpaired t-test was employed.
Results
Hexokinase activity in cancer cell lines
 Measurements of the enzymatic activity of hexokinase comprised 
the following types of hexokinases: HK I, II and III. Total hexokinase 
activity was measured in the cytosolic and mitochondrial fractions. 
In both human cancer cell lines (TMK-1, MiaPaCa-2), no difference 
in hexokinase activity in the cytosolic fractions was observed upon 
treatment with the Hsp90 inhibitor 17-DMAG (100 nM) (data not 
shown). In contrast, there was a significant decrease in hexokinase 
activity in the mitochondrial fractions of both human cancer cell 
lines treated with 17-DMAG compared to their untreated controls 
(Figure 1a and 1b). In parallel, hexokinase activity in TMK-1 and 
MiaPaCa-2 cancer cells transiently transfected with siRNA against 
Tom40 was determined. Similar to the treatment with 17-DMAG, 
a significant decrease in hexokinase activity in the mitochondrial 
fractions was observed (Figure 1a and 1b). Again, no hexokinase 
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activity difference in the cytosolic fractions was found when 
compared to control samples (data not shown). To exclude the 
possibility that these two treatments were acting through different 
pathways, 17-DMAG was applied to cells together with siRNA 
against Tom40. Results show that this possibility is unlikely, as the 
combination of Hsp90 inhibition with Tom40 knock-down did 
not increase the effect compared to either treatment applied alone 
(Figure 1a and 1b).
Subcellular localisation of Tom40, VDAC and HK II
Tom40: Tom40 is an integral part of TOM machinery known to 
localize to mitochondria and has been shown to be an Hsp90 
client protein. The aim of the following experiments was to 
determine in both human cancer cell lines potential changes in 
localization of Tom40, compared to control conditions, upon 
treatment with 17-DMAG or siRNA-mediated Tom40 knockdown. 
Under control conditions, Tom40 largely co-localized with 
mitochondria (Figure 2a and 2b top row). In contrast, cells treated 
with 17-DMAG showed a more dispersed distribution of Tom40 
protein compared to control conditions (Figure 2a and 2b middle 
row). This observation is also reflected by a significant increase in 
Tom40 area upon Hsp90 blockade (Figure 2a and 2b right side). 
Finally, direct blockade of Tom40 with siRNA led to a visible reduction 
in Tom40 staining intensity and only a minor change in the area of 
staining, as trafficking of the protein was not affected (Figure 2a and 2b). 
Together, these results suggest that Hsp90 inhibition causes changes in 
localization of Tom40 by preventing its successful trafficking/ 
assembly in the mitochondrial membrane.
HK II and VDAC: TOM complex facilitates membrane transfer of 
mitochondrial proteins coded in the nucleus including VDACs. 
VDACs on the other hand bind HK II and supply ATP necessary for 
its activity. While our previous results describe the changes in the 
localization and expression of Tom40 upon Hsp90 inhibition, it was 
necessary to assess the consequences of these changes on subcellular 
localisation of VDACs and HK II. Under control conditions HK II and 
VDACs co-localised to mitochondria and to each other (Figure 3a, 
and 3b top row). Co-localization of VDACs with HK II was confirmed 
by the fact that the areas occupied by these two proteins were 
essentially the same (within a 5% difference) for TMK-1 and 
MiaPaCa-2 cells (Figure 3a and 3b). Upon treatment with 17-DMAG 
for 72 h, co-localization of VDACs with HK II was reduced (Figure 3a 
and 3b middle row). Accordingly, the area covered by the HK II and 
VDAC staining was significantly increased. This result was consistent 
with the changes in subcellular localisation of HK II and VDACs, 
and a more dispersed localisation of these proteins (less overlap with 
mitochondria). Interestingly, a similar effect was observed when the 
cells were transiently transfected with Tom40 siRNA (Figure 3a and 
3b bottom row). Again, the area of staining for VDACs and HK II 
increased, whilst co-localization of these proteins with mitochondria 
was decreased. However, compared to 17-DMAG treatment, this 
increase was somewhat less pronounced. In conclusion, Hsp90 
inhibition affects subcellular distribution of VDACs and HK II in 
cancer cells via a Tom40-dependent mechanism.
Figure 1: Relative changes in total hexokinase activity in the mitochondrial 
fraction.
Total hexokinase activity measured in the mitochondrial fractions of 
a) TMK-1 and b) MiaPaCa-2 cells was significantly reduced upon 
treatment with Hsp90 inhibitor 17-DMAG (100nM), Tom40 blockade or 
both treatments together. Enzyme activity was measured after 72 h. 
Regular media conditions, transfection reagent (mock) and scrambled 
siRNA (neg. ctl.) served as controls. Differences in the total 
hexokinase activity between different conditions are shown as relative 
changes compared to normalized control (n=3 for each experiment; *P<0.05 
versus control).
Figure 2: Changes in Tom40 and mitochondria co-localisation in the presence 
of 17-DMAG and siRNA against Tom40.
TMK-1 (a) and MiaPaCa-2 (b) cells were grown on glass cover slips and stained 
with Tom40 (red) and Mitotracker (green) antibodies. Overlapping areas are 
shown in yellow. Under control conditions, Tom40 strongly co-localises with 
mitochondria (top row; yellow). In the case of Hsp90 inhibition with 17-DMAG 
(100 nM, 72 h), Tom40 (middle row, red) shows a more dispersed localization 
as compared to control; this is illustrated by a significant increase in Tom40 
area (*P<0.05, right side). Tom40 siRNA reduces expression of this protein, 
however, its co-localization with mitochondria remains the same (bottom row). 
Accompanying graphs show changes in the area occupied by Tom40 (right 
side). To facilitate comparison, images on the left were transformed into black 
and white staining of Mitotracker and Tom40. Statistics reflect a comparison of 
studied conditions versus controls. *P<0.05.
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Expression level of Tom40, HKs, VDACs and Hsp90
 To further assess these issues, expression of other hexokinases 
including HK I and HK III were studied in the mitochondrial and 
cytosolic fractions by Western blotting. Results show that expression 
of HK I and III is not appreciably affected by Hsp90 blockade with 
17-DMAG (100 nM, 72 h or Tom40 siRNA to a degree that is likely 
linked to decreased mitochondrial activity (Figure 4a and 4b). 
Interestingly, a slight to moderate increase in Hsp90 and Tom40 
protein expression was observed in both the cytosolic and 
mitochondrial fractions when cells were treated with 17-DMAG. 
However, this effect was not observed in cells with Tom40 
knockdown. Nevertheless, VDAC expression in the mitochondrial 
fraction was substantially decreased upon inhibition of either Hsp90 
or Tom40 (Figure 4a and 4b). This suggests that both treatments 
disturb Tom40 localization and activity and, in consequence, 
cause a change in intracellular distribution of VDACs and HK II. 
Interestingly, however, in the case of siRNA against Tom40 this 
occurred through decreased expression of Tom40, whilst Hsp90 
inhibition resulted in an increase in mitochondrial Hsp90 and Tom40. 
Hence, these effects were subsequently evaluated further.
Co-immunoprecipitation of Tom40 with Hsp90
 To explain the increased abundance of Tom40 and Hsp90 protein 
in the mitochondrial fraction after 17-DMAG treatment, 
co-immunoprecipitation of mitochondrial Tom40 with Hsp90 was 
performed. There was a clear increase in the abundance of Hsp90 
precipitated with Tom40 protein (Figure 5). This supports the idea 
that the increase in mitochondrial localisation of Hsp90 and Tom40 is 
due to a greater number of un-dissociated Hsp90/Tom40 complexes. 
This finding is a critical observation, because proteins require 
separation from Hsp90 to acquire proper folding.
Figure 3: Changes in VDAC co-localisation with HK II in the presence of 
17-DMAG and siRNA against Tom40.
TMK-1 (a) and MiaPaCa-2 (b) cells were stained with HK II (red), VDAC 
(green) and Mitotracker (blue). Under control conditions, VDACs co-localize 
with mitochondria and HK II (top row). This changes to a more dispersed 
localization upon treatment with Hsp90 inhibitor and Tom40 knockdown 
(middle and bottom row), as indicated by a significant increase in HK II and 
VDAC area (*P<0.05 versus control, right side). Accompanying graphs show 
changes in the area occupied by VDACs and HK II (right side). Statistics 
reflect a comparison of studied conditions versus controls. (*P<0.05).
Figure 4: Cytoplasmic and mitochondrial protein expression upon Hsp90 
inhibition and Tom40 blockade.
Assigned proteins were determined by Western blotting of TMK-1 (a) and 
MiaPaCa-2 (b) cells. No significant differences were observed in HK I and III 
expression levels in the cytoplasmic fraction. Nevertheless, Hsp90 and Tom 
40 expression were increased in cytoplasmic and mitochondrial fractions after 
treatment with 17-DMAG (100 nM, 72 h) in both cell lines. Mitochondrial VDAC 
expression was reduced in the presence of both 17-DMAG and Tom40 siRNA.
Figure 5: Reduced dissociation of Hsp90/Tom40 in mitochondria after Hsp90 
inhibition with 17-DMAG.
Mitochondrial protein was extracted from the cells kept under control 
conditions or treated with 17-DMAG (100 nM, 72 h). The first line (ctl WB) 
represents western blot performed on the non-co-immunoprecipitated 
protein. A control without antibody addition in the co-IP incubation mixture 
was performed (mock). There was an increase in Hsp90-Tom40 complexes 
upon Hsp90 inhibition, compared to control conditions. Results are shown for 
TMK-1; similar results were obtained for MiaPaCa2.
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Metabolic analysis
 HPLC-ESI-MS/MS analysis of intracellular succinate extracted 
from cells grown under assigned conditions was performed. 
Inhibition of Hsp90 with 17-DMAG (100 nM, 72 h) and 
siRNA-mediated Tom40 knockdown, respectively, led to a significant 
decrease in mitochondrial activity, as determined by the rate of 
synthesis of succinate from fully 13C-labelled glucose (Figure 6a). 
Analysis of media regarding glycolysis products of cells treated with 
17-DMAG showed a small, but significant increase in the release of 
lactate into the culture media (Figure 6b). To further check for the 
changes in the glycolytic activity of the studied cells measurements of 
the release/synthesis of serine and glycine were performed. A signifi-
cant increase in excretion of 13C-labelled serine was observed in both 
cell lines as well as an increase in release of 13C-labelled glycine in 
TMK-1 cells (Figure 6C). Serine and glycine are present in the culture 
medium and can be taken up by the cells. To illustrate extracellular 
changes in these metabolites we also plotted peak areas for 12C 
(uptake, shown as remaining substrate as compared to the level in 
blank media; Figure 6d). Cells treated with 17-DMAG (100 nM, 72 h) 
show less uptake of serine from the media. Together, these results 
suggest a metabolic shift towards glycolysis (as shown by increase 
in lactate and serine for both cell lines and glycine in the case of 
TMK-1) in the presence of decreased mitochondrial activity upon 
Hsp90 inhibition with 17-DMAG.
In vivo experiments
 The experiments were substantiated by in vivo experiments. 
A subcutaneous syngenic mouse model with murine PancO2 
pancreatic cancer cells was used. Mice were treated with 17-DMAG 
(25 mg/kg loading-dose, 10 mg/kg/d as a maintenance dose). 
Hexokinase activity and protein expression in cytosolic and 
mitochondrial fractions was assessed in tumor specimens extracted 
from control and 17-DMAG-treated animals. Results show that while 
total cytosolic hexokinase activity did not differ between the two 
groups (n=3 each), mitochondrial hexokinase activity was reduced 
significantly in tumors of 17-DMAG-treated mice (Figure 7a). 
Moreover, determination of the subcellular protein expression using 
Western blotting confirmed our in vitro results; mitochondrial VDAC 
expression was decreased, while Tom40 and Hsp90 levels were 
increased (Figure 7b).
Discussion
 Hsp90 plays a crucial role in oncogenesis by sustaining proper 
folding and trafficking of oncoproteins [2]. Therefore, Hsp90 
inhibitors are studied intensively as potential anti-cancer drugs [21]. 
Here, we have focused on the effects of Hsp90 interactions with the 
mitochondrial protein Tom40. While our study does not exclude that 
other proteins are also involved in metabolic control through the 
Hsp90 inhibition, similar effects of chaperone inhibition and Tom40 
knock-down do suggest Tom40 interactions with Hsp90 are a major 
cause of the observed metabolic alterations such as mitochondrial 
disruption and increase in glycolytic activity. Interestingly, the role 
of Hsp90 in cancer cell metabolism, in particular in glycolysis and 
mitochondrial respiration, has not been examined in detail. In the 
present study, we reveal a novel mechanism of Hsp90 action on cancer 
cell metabolism. 
Figure 6: Metabolomics.
Metabolomic analysis of cell pellets (a) and media (b-d). 4 mM [U-13C] 
glucose was added 24 h after the onset of treatment, which was carried out 
for a total of 72 h. The ratio of 13C-labelled to unlabeled intracellular succinate 
is presented for TMK-1 and MiaPaCa-2 a) cell lines A significant reduction 
of intracellular succinate synthesis was found with Hsp90 inhibitor present 
(*P<0.05) and Tom40 blockade (#P<0.05). b) Ion ratios for lactate in media 
indicate a significant increase in lactate secretion after 17-DMAG treatment. 
c) Release of 13C-labelled serine was significantly enhanced in both cell lines 
(*P<0.05). In TMK-1, an increase in glycine release was also observed. d) 
Cellular uptake of serine was decreased significantly upon Hsp90 inhibition, 
whereas only insignificant changes were found concerning glycine uptake. 
White histobars represent glycine and serine level in media. (n=3 per group; 
*P<0.05)
Figure 7: In vivo experiments.
a) Mitochondrial and cytoplasmic fractions extracted from mouse tumors 
were analyzed for HK II activity. A significant inhibition of mitochondrial HK II 
activity was observed upon treatment with 17-DMAG (*P<0.05; n=8). b) The 
mitochondrial tissues. Western blotting revealed a decrease in VDACs and an 
increase in Tom40 and Hsp90 expression.
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 Our experiments show, that blocking Hsp90 in cancer cells results 
in a shift of cellular metabolism towards glycolysis, reduced Krebs 
cycle activity, and a change in subcellular localization of 
metabolism-related proteins. In the absence of changes in overall 
protein expression [11], we show that sub-cellular localization of 
HK II is substantially affected by Hsp90 blockade. This effect was the 
result of an altered interaction of Hsp90 with its client protein Tom40 
[12,13], which is a part of the greater TOM complex [22]. Inhibition 
of Hsp90 resulted in higher Tom40 and Hsp90 abundance in the 
mitochondria. However, co-immunoprecipitation experiments 
showed that the observed increase was due to the presence of 
undissociated Hsp90-Tom40 complexes in the organelles. 17-DMAG 
is known to block the ATP site of Hsp90, which is needed for proper 
dissociation of the client protein from the chaperone [23]. Apparently, 
these complexes still target mitochondria but their inability to acquire 
proper TOM complex function triggers overexpression of Tom40 in 
the mitochondria and cytoplasm. This finding is consistent with the 
observation that ATP depletion results in Tom40 being arrested in 
large complexes consisting of Tom40, TOM machinery and cytosolic 
chaperones [12]. Therefore, our study shows, that while these 
Tom40-Hsp90 complexes still traffic to mitochondria, they do not 
dissociate in the presence of 17-DMAG. Interestingly, the use of 
novobiocin which is known to degrade Hsp90 client protein [24] 
reduces incorporation of Tom40 into the mitochondrial membrane 
[13]. A similar reduction was also observed when competitive Hsp90 
binding was applied [12]. In all the cases, including the present 
research, Hsp90 disruption resulted in a reduced or faulty 
incorporation of Tom40 into the mitochondrial membrane. It can 
therefore be reasonably deduced that Hsp90 takes part in trafficking 
of Tom40 to the mitochondrial membrane. Interestingly, a significant 
role of the mitochondrial Hsp90 in keeping energy production in 
cancer cells has been observed recently [25,26]. In can be, therefore, 
assumed that blocking Hsp90 activity results in mitochondrial 
disruption and metabolic changes, however, the exact mechanism 
depends on the drug used and the part of Hsp90 affected.
 Most mitochondrial proteins are coded for in the nucleus and are 
subsequently transferred through the mitochondrial membranes. 
Therefore, TOM disruption is expected to affect the abundance of 
several crucial molecules in this organelle, e.g. ion channels and 
transporters [27] that are responsible for proper exchange and 
communication between the mitochondria and cytoplasm. In our 
study we have focused on one of the major glycolytic enzymes, HK II. 
To acquire proper activity this enzyme needs to be attached to VDAC 
(believed to supply ATP for HK II; [28]), which is one of the most 
abundant and crucial mitochondrial communication channels [29]. 
We found that long-term inhibition of Hsp90 results in decreased 
VDAC expression in mitochondria and, in consequence, reduced 
abundance of HK II binding to the mitochondrial channels. We con-
clude, that Hsp90 inhibition affects mitochondrial import of VDACs 
and, thus, binding of HK II to the outer mitochondrial membrane.
 We also studied the consequences of Hsp90 inhibition-mediated 
changes to Tom40, HK II and VDAC on the Krebs cycle and 
glycolysis. Krebs cycle activity was determined as the ratio of 
incorporation of 13C from 13C labelled glucose into succinate, and 
was found to be decreased. This effect was expected because of the 
inability of mitochondria to properly exchange metabolites with the 
cytoplasm, resulting in Krebs cycle inhibition. In our research we have 
focused on VDACs abundance in the mitochondria in the presence 
of Hsp90 blocker. However, since TOM complex is involved in the 
import of most mitochondrial proteins, decreased mitochondrial 
activity is more likely related to the overall inhibited incorporation 
of several mitochondrial proteins including metabolic transporters 
such as pyruvate [30] or citrate [31]. Disruption in the abundance of 
mitochondrial channels and transporters could also alter 
mitochondrial membrane potential, additionally affecting Krebs cycle 
activity; this potential aspect will require further investigation.
 Glycolytic activity was assessed by measuring the ratio of 
incorporation of 13C from 13C labelled glucose into extracellular 
lactate, serine and glycine. Despite the fact that HK II binding to 
VDACs was decreased, overall glycolytic activity was increased. There 
was an accumulation of lactate, serine and, in the case of the gastric 
cancer cell line, glycine in the cells and supernatant. The increase in 
lactate might be explained by the reduced utilization of pyruvate in 
the Krebs cycle. As a consequence, it is rather converted to lactate. 
Interestingly, glycolytic activity shifted mainly towards serine/glycine 
synthesis in both cell lines. Serine is produced by phosphoglycerate 
dehydrogenase from 3-phosphoglycerate, one of the intermediates of 
the glycolytic pathway [32]. This shift could be explained by excess 
serine serving as a substrate to sustain metabolic equilibrium in 
the cells. Importantly, serine and glycine are precursors of many 
biosynthetic pathways leading to the production of amino acids, 
purines and pyrimidines. Additionally, during the conversion 
of 3-phosphoglycerate to serine, glutamate is metabolized into 
α-ketoglutarate [32]; α-ketoglutarate, in turn, is a precursor of other 
metabolites (e.g. citrate) necessary for fatty acid synthesis. Moreover, 
serine synthesis is accompanied by NADH production needed to 
maintain red/ox balance. Therefore, enhancement of this 
serine-producing pathway via Hsp90 inhibition could partially 
compensate for the reduced abundance of cytosolic metabolites 
normally supplied by mitochondria. In fact, increased synthesis of 
serine and glycine derived from glycolysis has been associated with 
some types of cancer [33,34]. The slight differences in regulation of 
the serine/glycine ratio observed in the two cancer cell lines studied 
is likely due to the cells originating from different tissues (pancreas 
versus stomach). 
 Previous research has shown that targeting Hsp90 reduces tumor 
growth in vivo [10,16]; in vitro studies suggest this effect may be 
related to increased cell death [35]. However, we speculate from our 
results that although the overall cell number and tumor growth may 
be reduced under Hsp90 inhibition, the surviving cells will likely 
retain metabolic characteristics that potentially correlate with a 
high metastatic potential, such as increased glycolysis and serine 
synthesis. This finding raises concerns about Hsp90 inhibitory therapy 
that needs to be further researched.
Conclusions
 To conclude, the present study shows that Hsp90 inhibition 
reduces mitochondrial respiration and increases glycolysis in 
the studied cancer cells, shifting metabolism mainly towards 
serine/glycine synthesis. These changes occur due to the disrupted 
interactions between Hsp90 and Tom40 indicating that Hsp90 
supports mitochondrial biogenesis by assuring assembly of TOM. 
The overall shift towards glycolysis (a phenomenon associated with 
metastatic behavior of cancer cells) due to disrupted trafficking of 
mitochondrial proteins should be considered when applying Hsp90 
inhibitors in clinics.
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